Table 3.
Transplant outcomes for B-ALL patients at different time points after allo-SCT.
| MRD status at different time points | 5-year relapse | P value | 5-year OS | P value | 5-year LFS | P value | 5-year NRM | P value |
| +30 days | <0.001 | <0.001 | <0.001 | 0.416 | ||||
| MRD− | 21.7 (17.6–25.8) | 72.6 (68.5–76.7) | 67.7 (63.4–72.0) | 13.5 (10.4–16.6) | ||||
| MRD+ | 52.3 (28.2–76.4) | 36.8 (15.0–58.6) | 36.8 (15.0–58.6) | 18.9 (0–38.5) | ||||
| +60 days | <0.001 | <0.001 | <0.001 | 0.792 | ||||
| MRD− | 21.6 (17.5–25.7) | 73.3 (69.2–77.4) | 68.3 (64.0–72.6) | 12.6 (9.5–15.7) | ||||
| MRD+ | 61.1 (35.8–86.4) | 33.3 (9.4–57.2) | 33.3 (9.4–57.2) | 11.1 (0–31.7) | ||||
| +90 days | <0.001 | 0.002 | <0.001 | 0.230 | ||||
| MRD− | 20.4 (16.5–24.3) | 75.4 (71.3–79.5) | 70.7 (66.4–75.0) | 11.0 (8.1–13.0) | ||||
| MRD+ | 70.0 (46.9–93.1) | 42.8 (18.5–67.1) | 30.0 (6.9–53.1) | 0 | ||||
| +120 days | <0.001 | <0.001 | <0.001 | 0.285 | ||||
| MRD− | 19.8 (15.9–23.7) | 76.8 (72.9–80.7) | 71.5 (67.2–75.8) | 10.7 (7.8–13.6) | ||||
| MRD+ | 73.3 (51.0–95.6) | 26.7 (4.4–49.0) | 26.7 (4.4–49.0) | 0 | ||||
| +180 or more days | <0.001 | <0.001 | <0.001 | 0.066 | ||||
| MRD− | 13.9 (10.2–17.6) | 82.8 (79.1–86.0) | 79.1 (75.0–83.2) | 8.2 (5.5–10.9) | ||||
| MRD+ | 75.0 (60.7–89.3) | 33.6 (14.8–52.4) | 25.0 (10.7–39.3) | 0 |
Data are presented as percentage of incidence (95% confidence interval). allo-SCT: Allogeneic stem cell transplantation; B-ALL: B cell acute lymphocytic leukaemia; LFS: Leukemia-free survival; MRD: Minimal residual disease; NRM: Non-relapse mortality; OS: Overall survival.